Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic
Pancreatic
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-nave patients with metastatic pancreatic adenocarcinoma (PDAC).
Pancreatic
II
Cardin, Dana
NCT07259317
VICCGI26013
